We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.72 | -0.56% | 128.50 | 129.93 | 127.80 | 129.43 | 5,895,709 | 01:00:00 |
By Colin Kellaher
Merck & Co. Tuesday said a pivotal Phase 3 study of its cancer drug Keytruda in combination with chemotherapy met a primary endpoint of overall survival in metastatic triple-negative breast cancer.
The Kenilworth, N.J., drugmaker said the combination showed a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone in patients whose tumors expressed PD-L1 with a combined positive score of at least 10.
Merck said Keytruda is the first anti-PD-1 therapy in combination with chemotherapy to show statistically significant overall survival for that patient population. The company previously reported that the combination had shown significantly improved progression-free survival.
Merck is studying Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, across multiple settings and stages of triple-negative breast cancer, the subtype with the worst survival prognosis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 27, 2021 07:42 ET (11:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions